BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

30 11 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

14 11 2022 07:00:02 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

10 11 2022 07:00:04 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022

27 10 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

05 10 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

07 9 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

09 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

03 8 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

26 7 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

05 7 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

07 6 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

20 5 2022 07:00:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

09 5 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

05 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

03 5 2022 07:00:02 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

26 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

19 4 2022 07:05:00 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

19 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

06 4 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

10 3 2022 07:04:55 提供 Nasdaq GlobeNewswire